Last Updated: July 3, 2026

Suppliers and packagers for SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE


✉ Email this page to a colleague

« Back to Dashboard


SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Alkem Labs Ltd SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE magnesium sulfate; potassium sulfate; sodium sulfate SOLUTION;ORAL 213924 ANDA Ascend Laboratories, LLC 67877-725-92 2 BOTTLE, PLASTIC in 1 CARTON (67877-725-92) / 177 mL in 1 BOTTLE, PLASTIC 2024-03-29
Annora Pharma SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE magnesium sulfate; potassium sulfate; sodium sulfate SOLUTION;ORAL 212903 ANDA Camber Pharmaceuticals, Inc. 31722-098-31 2 BOTTLE, PLASTIC in 1 CARTON (31722-098-31) / 177 mL in 1 BOTTLE, PLASTIC (31722-098-17) 2024-10-18
Annora Pharma SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE magnesium sulfate; potassium sulfate; sodium sulfate SOLUTION;ORAL 212903 ANDA NorthStar RxLLC 72603-278-02 2 BOTTLE, PLASTIC in 1 CARTON (72603-278-02) / 177 mL in 1 BOTTLE, PLASTIC (72603-278-01) 2025-03-01
Bionpharma SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE magnesium sulfate; potassium sulfate; sodium sulfate SOLUTION;ORAL 204135 ANDA Bionpharma Inc., 69452-428-62 2 BOTTLE, PLASTIC in 1 KIT (69452-428-62) / 177 mL in 1 BOTTLE, PLASTIC 2025-04-15
Novel Labs Inc SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE magnesium sulfate; potassium sulfate; sodium sulfate SOLUTION;ORAL 202511 ANDA Novel Laboratories, Inc. 40032-700-83 2 BOTTLE in 1 CARTON (40032-700-83) / 177 mL in 1 BOTTLE 2017-02-23
Novel Labs Inc SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE magnesium sulfate; potassium sulfate; sodium sulfate SOLUTION;ORAL 202511 ANDA Lupin Pharmaceuticals, Inc. 43386-700-83 2 BOTTLE in 1 CARTON (43386-700-83) / 177 mL in 1 BOTTLE 2022-12-30
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers and packagers for SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

Last updated: May 26, 2026

Suppliers for Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate (API and excipient-grade): who sells, what grades, and how to qualify

Executive summary: Sodium sulfate, potassium sulfate, and magnesium sulfate are commodities with broad global supply. Supplier qualification and pricing leverage usually hinge on grade (USP/NF, BP, ACS, industrial), specification system (assay, impurities, particle size), cGMP status, supply reliability, and regulatory paperwork (DMF/CoA/CEP/DMF access). For formulators, the practical supplier universe splits into (1) specialty chemical producers offering USP/NF or food/pharma grades and (2) commodity chemical manufacturers with weaker documentation depth for drug applications. For pharmaceutical use, the shortlist typically centers on vendors that can consistently deliver pharma-grade CoAs, traceable lots, and cGMP or ISO 9001/14001 operating models, with documented impurity controls for sulfates, metals, chloride, and water content.


Who are the main suppliers of sodium sulfate for pharmaceutical use (USP NF, ACS, excipient)?

Direct answer: Sodium sulfate suppliers for pharma-grade sourcing are typically chemical producers and distributors that offer one or more of: USP/NF, ACS, BP, food grade, and technical grade.

Common pharma-grade supply categories

  • USP/NF sodium sulfate (commonly used as an osmotic agent, processing aid, or electrolyte system component depending on the product)
  • BP/EP-compliant grades (used in EU formulations)
  • ACS grade (often used in lab and some manufacturing contexts, less frequently accepted for regulated pharmaceutical compounding unless documentation is strong)
  • Food grade (sometimes used in lower-risk applications; regulatory acceptance depends on route and drug quality system)

Specification points that drive pharma acceptance

  • Assay and purity: sodium sulfate content
  • Impurity ceilings: chloride, insoluble matter, heavy metals
  • Water of crystallization / anhydrous designation
  • Granulation / particle size (affects dissolution and mixing uniformity)
  • Microbial limits (less common for inorganic salts but required for some QA regimes)

Typical “supplier archetypes” for sodium sulfate

  • Global inorganic chemical manufacturers producing sodium sulfate at scale and offering pharma/food grades through segregated packaging and documentation.
  • Pharma excipient distributors who provide batch documentation and manage regulatory paperwork but may source through multiple upstream producers.

Which companies supply potassium sulfate for pharma formulations and excipient needs?

Direct answer: Potassium sulfate suppliers for pharmaceutical applications are usually inorganic chemical manufacturers offering pharma/USP-aligned documentation and distributors with controlled-lot sourcing.

Pharma-critical quality attributes for potassium sulfate

  • Potency/assay (minimum potassium sulfate content)
  • Chloride limits
  • Sodium content (often relevant in electrolyte formulations)
  • Sulfate purity and insoluble residue
  • Heavy metals and iron limits (commonly specified in pharmacopeias)
  • Moisture and particle size distribution

What drug manufacturers actually demand from potassium sulfate suppliers

  • Lot-by-lot CoA referencing the relevant specification system
  • Impurity trend data or validated impurity profiles if the material affects product CQAs
  • Controlled packaging and labeling (e.g., drum vs bag, internal ID, traceability)

Where to source magnesium sulfate for pharmaceutical manufacturing (USP NF, Heptahydrate vs anhydrous)?

Direct answer: Magnesium sulfate supply for pharma use is best approached by identifying whether the target is magnesium sulfate heptahydrate or anhydrous magnesium sulfate, then selecting suppliers that support the correct form with controlled impurity and water content.

Magnesium sulfate form matters

  • Magnesium sulfate heptahydrate: critical for products where water content impacts osmolality, concentration accuracy, dissolution behavior, or stability.
  • Anhydrous magnesium sulfate: used where water uptake must be controlled.

Pharma-quality attributes

  • Water of crystallization specification
  • Chloride and sulfate purity
  • Heavy metals (especially Mg impurities that can affect downstream assays or patient safety concerns)
  • Particle size and flow properties for powder handling

Do sodium sulfate, potassium sulfate, and magnesium sulfate suppliers offer USP/NF or BP/EP compliant grades?

Featured snippet: Yes for many suppliers in the market, but pharma-grade availability is inconsistent across regions and across product forms.

How to verify “USP/NF compliant” in procurement

  • CoA explicitly states the monograph/specification (USP <…> references when applicable).
  • Supplier provides batch release documentation traceable to the specific grade and form.
  • For regulated manufacturing, buyers generally require a document pack that can be audited by QA.

Grade labeling pitfalls

  • “USP compliant” sometimes means “intended to meet” rather than meeting the exact monograph. Procurement should rely on documented CoA and specification ownership by the supplier or buyer.

What supplier documentation is required for pharmaceutical salts like sulfate excipients?

Direct answer: Buyers typically require a quality package covering traceability, specification, and regulatory suitability.

Standard documentation set

  • Certificate of Analysis (CoA), lot traceability
  • Material Safety Data Sheet (SDS)
  • Quality certifications: ISO 9001 (common), ISO 14001 (common)
  • Compliance statements for pharmacopeia alignment (when offered)
  • For some customers: audit reports or GMP manufacturing assertions
  • Impurity declarations and change notification terms

QA/QC checks buyers run on inorganic salts

  • Identity by suitable analytical method
  • Assay and impurity testing aligned to the incoming acceptance specification
  • Verification of water content for hydrated forms (magnesium sulfate heptahydrate)

How do you qualify and audit suppliers for sulfate salts in drug manufacturing?

Direct answer: Qualification is typically executed via risk-based supplier qualification, document review, incoming testing, and supplier audit where required by the buyer’s quality system.

Qualification workflow (typical)

  1. Document review: grade definitions, spec sheets, CoA history, change control terms
  2. Technical assessment: impurity profile fit for product CQAs
  3. Initial lots: incoming release testing and stability/handling checks if relevant
  4. Audit (when required): facility process controls and traceability

Key audit focus areas for inorganic salts

  • segregation between food/tech/pharma grades
  • chain-of-custody and packaging controls
  • impurity control methodology (source material controls)
  • change control for process, suppliers, and packaging

What are the main global regions for sodium sulfate, potassium sulfate, and magnesium sulfate supply?

Direct answer: Production is concentrated where inorganic chemical capacity is dense: China, Europe, and parts of the Middle East and India, with additional supply through the Americas via distributors and regional manufacturers.

Practical sourcing guidance

  • Global procurement often shifts between direct manufacturer and distributor models.
  • Lead times and continuity of supply matter because inorganic salt demand can be seasonal and linked to industrial cycles.

How do lead times and pricing dynamics differ between sulfate salts and pharma-grade requirements?

Direct answer: Commodity price swings can be sharper at the industrial grade level; pharma-grade documentation adds friction through batch segregation, QA release processes, and controlled packaging.

What changes when switching grades or forms

  • Heptahydrate vs anhydrous magnesium sulfate changes the supply base and moisture controls.
  • Supplier grade segregation can add cost even when the base chemistry is the same.

Which supplier model is safer for regulatory submissions: direct manufacturer or pharma distributor?

Direct answer: For controlled submissions and consistent audit trails, direct manufacturer is typically preferred. Distributors can work when they provide traceable lot documentation and can disclose upstream manufacturing practices.

Decision drivers

  • ability to provide upstream impurity controls
  • ability to support regulatory audits
  • stability of documentation and change notifications
  • willingness to share quality agreements and batch release terms

What competitive landscape exists for sulfate salt excipients in drug manufacturing?

Direct answer: Competition is broad but segmented by documentation capability and grade segregation. Many suppliers can sell the salts; fewer can support consistent pharma-grade compliance at scale with robust QA documentation.

Where competition compresses margins

  • standard grades (ACS/technical/food)
  • regions with multiple inorganic chemical producers
  • distributor channels where paperwork is the primary differentiator

Where supplier pricing holds up

  • pharma-grade assured supply
  • validated segregation and low impurity consistency
  • reliable forms and packaging specs needed for cGMP dosing operations

Key Takeaways

  • Sodium sulfate, potassium sulfate, and magnesium sulfate are widely available, but pharmaceutical-grade acceptance depends on documentation, grade segregation, and impurity control.
  • Magnesium sulfate supply is form-specific (heptahydrate vs anhydrous), with different water-content and impurity considerations.
  • Supplier qualification is typically risk-based: document pack review, incoming testing, and audit where required.
  • The procurement strategy that reduces regulatory friction is usually direct-to-manufacturer for controlled grades or a distributor with strong upstream transparency and stable lot traceability.

FAQs

  1. Can I use industrial-grade sodium sulfate in pharmaceutical manufacturing?
    Use depends on the buyer’s quality system, impurity risk assessment, and the acceptability of documentation and specification alignment via lot-by-lot CoA.

  2. What impurity profile matters most for potassium sulfate in drug products?
    Typically chloride, sodium content, heavy metals, and insoluble residue are key for many formulations.

  3. Is magnesium sulfate heptahydrate always interchangeable with anhydrous magnesium sulfate?
    No. Water content differences can affect concentration accuracy, osmolality, handling, and downstream quality attributes.

  4. Do distributors need to provide upstream manufacturing information for sulfate salts?
    For pharma-grade sourcing, buyers commonly require traceability and quality agreements, and may require audit access depending on risk.

  5. How do supplier changes (source, process, packaging) impact inorganic excipients?
    Changes can alter particle size, moisture behavior, and impurity profiles, so buyers typically require change notifications and may retest bridging lots.


References

  1. USP-NF (United States Pharmacopeia and National Formulary). Relevant monographs for sodium sulfate, potassium sulfate, and magnesium sulfate.
  2. European Pharmacopoeia (Ph. Eur.). Relevant monographs for sodium sulfate, potassium sulfate, and magnesium sulfate.
  3. FDA. Guidance for Industry: Submitting Documentation for the Use of Excipients in Food Contact Substances / Drug Products (as applicable to excipient quality and documentation practices).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.